156 CHAPTER 8 S3: EXTRACTED STUDY AND PATIENT CHARACTERISTICS. Study characteristics Data source (i.e. electronic health record, prospective registry) Country Setting (i.e. general care, specialist care, both) Time frame (i.e. inclusion period) NOAC (i.e. dabigatran, rivaroxaban, apixaban, edoxaban) Guideline used to determine whether a non-reduced or a reduced NOAC dose was indicated (i.e. SPC, FDA, ESC, EHRA, landmark NOAC trials, other guideline, not reported) Number of included patients with AF who use a NOAC Duration of follow-up in months Patient characteristics Male sex in percentage Age in years in mean (or median) Weight in kilograms in mean (or median) Body mass index in mean (or median) eGFR (or CrCl) in mean (or median) Patients with an eGFR <50 in percentage Patients with hypertension in percentage Patients with a history of (ischemic) stroke (and TIA and/or thromboembolism) in percentage (including definition) Patients with a history of hemorrhagic stroke in percentage Patients with (a history of) coronary heart disease in percentage (including definition) Patients with (a history of) (peripheral) vascular disease in percentage Patients with heart failure in percentage Patients with (a history of) other cardiovascular disease in percentage (including definition) Patients with diabetes mellitus in percentage Patients with chronic kidney disease in percentage (including definition) Patients using concomitant drugs that interact with NOACs in percentage (including the type of drug) AF: atrial fibrillation; CrCl: creatinine clearance; eGFR: estimated Glomerular Filtration Rate; EHRA: European Heart Rhythm Association; ESC: European Society of Cardiology; FDA: Food and Drugs Administration; NOAC: non-vitamin K antagonist oral anticoagulant; SPC: Summary of Product Characteristics; VKA: vitamin K antagonist.
RkJQdWJsaXNoZXIy MTk4NDMw